Xconomy National

Archives

by in
Entry Author Date Location
Genentech, ImmunoGen’s Souped-Up Antibody for Breast Cancer Passes Key Test Luke Timmerman 09/24/11 San Francisco
Vertex Gets FDA OK, Alnylam Plans For ASCO, Biogen Drug Advances in Europe, & More Boston-Area Life Sciences News Erin Kutz 05/27/11 Boston
ImmunoGen Grabs $84M Luke Timmerman 05/20/11 Boston
RXi Sells Stock and Warrants, Cardiorobotics Raises $6.6M, ImmunoGen Dishes On New Drugs, & More Boston-Area Life Sciences News Erin Kutz 03/04/11 Boston
ImmunoGen CEO Highlights Two New Souped-Up Antibodies Against Cancer Ryan McBride 02/25/11 Boston
Adriana Jenkins, Boston Biotech PR Maven, Dies from Breast Cancer at 41 Luke Timmerman 02/10/11 Boston
Alkermes Drug Approved for Opioid Addiction, Genzyme Faces Shareholder Lawsuits, NinePoint Gets $33M, & More Boston-Area Life Sciences News Erin Kutz 10/15/10 Boston
ImmunoGen Inks $45M Deal With Novartis, Tata Leads $9.5M Sun Catalytix Deal, InfraReDx Gets $21M, & More Boston-Area Deals News Erin Kutz 10/13/10 Boston
ImmunoGen Gets $45M Upfront From Novartis To Make Souped Up Antibodies For Cancer Luke Timmerman 10/11/10 Boston
Genentech’s Souped-Up Breast Cancer Drug Beats Original Herceptin in Head-to-Head Study Luke Timmerman 10/08/10 San Francisco
PerkinElmer Sells Unit for $500M, Aveo Stock Climbs, Pfizer Buys FoldRx, & More Boston-Area Life Sciences News Erin Kutz 09/03/10 Boston
ImmunoGen and Genentech “Empowered Antibody” Cancer Drug Fails to Garner Accelerated Approval from FDA Erin Kutz 08/27/10 Boston
Genentech Agrees to Pay Seattle Genetics Up to $900M for “Empowered Antibodies” Luke Timmerman 08/03/10 Seattle
Genentech Seeks FDA Nod for T-DM1 Luke Timmerman 07/07/10 San Francisco
Genentech’s Souped-Up Herceptin: The Odyssey Toward a More Powerful Breast Cancer Drug Luke Timmerman 06/14/10 San Francisco
Biogen CEO Retires, Genzyme Board Nominates Amgen Vet and Strikes Deal with Icahn, Xconomy Spotlights Life Sciences XSITE Speakers, & More Boston-Area Life Sciences News Erin Kutz 06/11/10 Boston
XSITE’s Biotech Gurus to Cover the State of New England Biotech, the Return of Platforms Luke Timmerman 06/07/10 Boston
Scripps Chemistry Idea “Clicks” With Big Pharma, Seattle’s Integrated Diagnostics Luke Timmerman 05/19/10 San Diego
Oxford’s Fambrough Leaves for Dicerna, Clinical Data Aims to Take on Big Pharma with Antidepressants, Genzyme’s Termeer Courts Shareholders, & More Boston-Area Life Sciences News Erin Kutz 05/14/10 Boston
ImmunoGen Raises $67M in Stock Deal Luke Timmerman 05/06/10 Boston
Celldex CEO Treks From NJ to Massachusetts in Pursuit of Antibody Drugs for Cancer Luke Timmerman 02/23/10 Boston
Seattle Genetics Maps Out a Future With Antibody Drugs That Are “Empowered” Luke Timmerman 01/06/10 Seattle
Ambrx, Saying Thanks to its Rivals, Rides Wave of Interest in “Empowered” Antibodies Luke Timmerman 01/06/10 San Diego
Biogen Idec Board in Flux, Cubist Acquires Calixa, ImmunoGen Drug Passes Clinical Test, & More Boston-Area Life Sciences News Rebecca Zacks 12/16/09 Boston
Breast Cancer “Smart Bomb” Drug From Roche, ImmunoGen Passes Important Trial Luke Timmerman 12/12/09 Boston
Breast Cancer “Smart Bomb” From Roche, ImmunoGen Shows Tumor Shrinkage in Big Test Luke Timmerman 12/09/09 Boston
A Graceful Exit for Gloucester, Pink Slips at Sermo, A Half a Billion Bucks for Vertex, & More Boston-Area Life Sciences News Rebecca Zacks 12/09/09 Boston
Supercharged Herceptin Nears Pivot Point, as ImmunoGen, Roche Await Data on Breast Cancer “Smart Bomb” Luke Timmerman 12/07/09 Boston
Ironwood Pharma Eyes $172.5M IPO, Biogen CEO Pay Under Fire, & More Boston Life Sciences News Ryan McBride 11/25/09 Boston
Metcalfe Reflects on $2.7B 3Com Buyout, MyPunchbowl Parent Adds New Punch, $30M More for Fate Therapeutics, & More Boston Deals News Ryan McBride 11/20/09 Boston
Page 1 of 2 next page »
    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.